Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group
The DOI matches its Crossref record.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because marimastat has previously progressed to clinical trials as a cancer treatment, its safety profile has already been determined, accelerating its development as a potential snakebite treatment (63, 64).”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 9
- Comis RL: DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep 60:165–176, 1976
- Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HKB, Verma S, Armitage GR, Zee B, Bennett K: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:2083–2090, 1996 · DOI · Paper page
- Kirkwood JM, Ernstoff M: Melanoma: Therapeutic options with recombinant interferons. Semin Oncol 13Suppl 5:7–12, 1985
- Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR, Doroshow JH, Aronson FR, Rubenstein LV, Mier JW: A randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon-? 2A in patients with advanced melanoma. J Clin Oncol 11:1969–1977, 1993 · DOI
- Brown PD, Giavazzi R: Matrix metalloproteinase inhibition: A review of antitumor activity. Ann Oncol 6:967–974, 1995 · DOI · Paper page
- Brown PD, Bloxidge RE, Stuart NSA, Gatter KC, Carmichael J: Association between expression of activated 72-kilodalton gelatinase and tumour spread in non-small cell lung cancer. J Natl Cancer Inst 85:574–578, 1993 · DOI
- Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Activity of type IV collagenases in benign and malignant breast tissue. Br J Cancer 67:1126–1131, 1993 · DOI · Paper page
- Smyth-Templeton N, Brown PD, Levy AT, Margulies IM, Liotta LA, Stetler-Stevenson WG: Cloning and characterization of human melanoma interstitial collagenase. Cancer Res 50:6184–6191, 1990
- Chirivi RGS, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD, Giavazzi R: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460–464, 1994 · DOI · Paper page
Cited by
Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Dulak, J., & Jozkowicz, A. (2005) · Current Cancer Drug Targets · doi:10.2174/156800905774932824 · Cited by 235
Smith, C. F., Modahl, C. M., Ceja Galindo, D., Larson, K. Y., Maroney, S. P., Bahrabadi, L., Brandehoff, N. P., Perry, B. W., McCabe, M. C., Petras, D., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100779 · Cited by 11
Metadata
- Authors
- Quirt, I., Bodurtha, A., Lohmann, R., Rusthoven, J., Belanger, K., Young, V., Wainman, N., Steward, W., & Eisenhauer, E.
- Venue
- Investigational New Drugs
- Published
- 2002-11
- Volume
- 20
- Issue
- 4
- Pages
- 431-437
- ISSN
- 0167-6997
- 1573-0646
- Cited by
- 36
- References
- 0
- Language
- en
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.